ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Evaluation of PET CT in the Management of Patients With Crohn's Disease.

This study is not yet open for participant recruitment.
Verified by Rabin Medical Center, February 2008

Sponsored by: Rabin Medical Center
Information provided by: Rabin Medical Center
ClinicalTrials.gov Identifier: NCT00731809
  Purpose

18F-FDG PET/CT (2-[fluorine-18] fluoro-2-deoxy-D-glucose, Positron emission tomography- CT) is a noninvasive technique that allows quantifying and precisely localizing 18F-FDG uptake in the entire body. 18F-FDG uptake is caused by increased local metabolic activity. Such increased uptake has been described not only in neoplastic lesions but also in inflammatory lesions. In this condition, uptake has been correlated with local stimulation of tumor necrosis factor, and with monocyte priming and activation. A physiologic variable uptake may be observed in the bowel, especially the cecum, and has limited the use of PET in inflammatory bowel diseases. The advantage of combined PET and CT devices lead to significant improvements in the interpretation of the bowel areas, and greatly reduces the number of false-positive findings in the gastrointestinal tract.


Condition Intervention
Crohn's Disease
Radiation: FDG PET CT

Genetics Home Reference related topics:   Crohn disease   

MedlinePlus related topics:   Crohn's Disease   

U.S. FDA Resources

Study Type:   Interventional
Official Title:   Evaluation of PET CT in the Management of Patients With Crohn's Disease.

Further study details as provided by Rabin Medical Center:

Arms Assigned Interventions
1
PET CT
Radiation: FDG PET CT
FDG PET CT

  Eligibility
Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Patients suspicious for active disease:

    • Patients with suspected but undiagnosed Crohn's disease
    • Patients with serological markers of inflammation (elevated ESR, CRP or thrombocytosis) but clinically in remission
    • Patients with a stricture which might be fibrous in which case surgery is indicated or inflammatory for which medical management is indicated
    • Able to sign a consent form

Exclusion Criteria:

  • Pregnancy
  • Breastfeeding
  • Infectious colitis determined at the initial checkup
  • Allergy to iodine contrast
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00731809

Locations
Israel
Rabin Medical Center    
      Petah-tikva, Israel, 49100

Sponsors and Collaborators
Rabin Medical Center
  More Information


Study ID Numbers:   004945
First Received:   August 3, 2008
Last Updated:   August 7, 2008
ClinicalTrials.gov Identifier:   NCT00731809
Health Authority:   Israel: Ethics Commission

Keywords provided by Rabin Medical Center:
Crohn's disease  

Study placed in the following topic categories:
Digestive System Diseases
Gastrointestinal Diseases
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Intestinal Diseases

ClinicalTrials.gov processed this record on October 31, 2008




Links to all studies - primarily for crawlers